Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals plc, a commercial-stage biopharmaceutical company, in a transaction valued at approximately $2.1 billion. Under the terms of the agreement, Alkermes will pay up to $20.00 per share in cash, including a contingent value right (CVR) of $1.50 per share tied to regulatory milestones. The acquisition price represents a 38% premium to Avadel’s three-month volume-weighted average share price and a 12% premium to its ...